{"id":1896,"date":"2026-07-09T22:22:21","date_gmt":"2026-07-10T02:22:21","guid":{"rendered":"https:\/\/www.insilens.com\/?p=1896"},"modified":"2026-07-09T22:23:24","modified_gmt":"2026-07-10T02:23:24","slug":"telo-genomics-patents-liquid-biopsy-myeloma-mrd","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=1896","title":{"rendered":"Telo Genomics Patents Liquid Biopsy Myeloma MRD"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Company<\/strong><\/p>

Telo Genomics Corp. (TSXV: TELO; OTCQB: TDSGF)<\/p>

Event Type<\/strong><\/p>

U.S. provisional patent application filing \u2014 intellectual property expansion<\/p>

Modality<\/strong><\/p>

Liquid biopsy minimal residual disease (MRD) diagnostics \u2014 3D telomere quantitative analysis with AI-based genetic instability recognition<\/p>

Platform<\/strong><\/p>

TeloView biomarker algorithm<\/p>

Indication<\/strong><\/p>

Multiple Myeloma \u2014 MRD management<\/p>

Summary<\/strong><\/p>

Telo Genomics filed a U.S. provisional patent application to protect a new TeloView biomarker algorithm designed for use with liquid biopsy samples, including those at minimal residual disease levels, in the management of patients with multiple myeloma. The algorithm is intended to predict relapse risk and to define a workflow for isolating circulating cancer cells from peripheral blood in the MRD setting.<\/p>

The TeloView platform quantifies three-dimensional telomere architecture as a marker of genomic instability, combining this signal with molecular biology and artificial intelligence to detect disease-associated genetic aberration. The company reports the underlying technology has been substantiated across more than 160 peer-reviewed publications and 30 clinical studies involving over 3,000 patients.<\/p>

\u00a0<\/p>

Why It Matters<\/strong><\/p>

Minimal residual disease has become one of the most consequential measures in multiple myeloma \u2014 increasingly central to clinical trial design, regulatory endpoints, and treatment sequencing decisions. Current MRD assessment predominantly requires bone marrow aspiration, an invasive procedure poorly suited to the frequent, longitudinal monitoring that modern myeloma management demands, and one that samples only a single anatomic site of a spatially heterogeneous disease.<\/p>

A validated peripheral-blood MRD assay would reduce dependence on serial bone marrow sampling, enable more frequent disease monitoring, and better capture the spatial heterogeneity that single-site marrow biopsy misses. Blood-based MRD is a strategically important complement to established bone marrow-based methods.<\/p>

Competitive Context<\/strong><\/p>

Blood-based MRD in myeloma is an actively contested field, with next-generation sequencing (clonoSEQ), mass spectrometry, and circulating tumor cell approaches all competing to reduce reliance on marrow sampling. TeloView’s differentiation rests on 3D telomere-based genomic instability quantification \u2014 a mechanistically distinct biomarker from immunoglobulin sequence tracking or M-protein detection.<\/p>

\u00a0<\/p>

Signal Strength Rationale<\/strong><\/p>

Rated Signal 3 \u2014 Meaningful. This is a diagnostics and IP signal rather than a therapeutic advance, but it is directly relevant to hematology given the escalating clinical and regulatory weight of MRD in myeloma. Rating reflects patent-stage status without prospective clinical validation of the specific liquid biopsy algorithm. Upgrade trigger: prospective clinical validation data or a commercial diagnostic partnership.<\/p>

Forward Catalyst<\/strong><\/p>

Validation studies of the peripheral-blood TeloView MRD algorithm and potential commercial partnerships would determine whether the patented approach translates into a clinically adopted assay.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

Company Telo Genomics Corp. (TSXV: TELO; OTCQB: TDSGF) Event Type U.S. provisional patent application filing \u2014 intellectual property expansion Modality Liquid biopsy minimal residual disease (MRD) diagnostics \u2014 3D telomere quantitative analysis with AI-based genetic instability recognition Platform TeloView biomarker algorithm Indication Multiple Myeloma \u2014 MRD management Summary Telo Genomics filed a U.S. provisional patent […]<\/p>\n","protected":false},"author":1,"featured_media":1897,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,4],"tags":[],"class_list":["post-1896","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-technology-modalities"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/1896","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1896"}],"version-history":[{"count":4,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/1896\/revisions"}],"predecessor-version":[{"id":1901,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/1896\/revisions\/1901"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/1897"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1896"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1896"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1896"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}